Opportunity
Federal Register #2026-19400
DEA proposes Schedule I placement for five tryptamine hallucinogens
Buyer
Drug Enforcement Administration
Posted
September 23, 2026
Respond By
October 23, 2026
Identifier
2026-19400
This regulatory action from the Drug Enforcement Administration (DEA) proposes new controls for specific hallucinogenic substances. - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA) - Substances Proposed for Schedule I Placement: - 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT) - 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) - 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) - 5-methoxy-N,N-diethyltryptamine (5-MeO-DET) - N,N-diisopropyltryptamine (DiPT) - Includes salts, isomers, and salts of isomers - No OEMs or commercial vendors are involved; this is a regulatory proposal, not a procurement - No products or services are being requested; the action is to impose regulatory controls - Notable Requirements: - Compliance with Schedule I controls for manufacturing, distribution, research, import, export, and possession - Opportunity for public comment and hearings - Based on scientific and medical evaluations and recommendations from HHS - The rule targets substances with high abuse potential and no accepted medical use in the U.S.
Description
The Drug Enforcement Administration (DEA) proposes to place five tryptamine hallucinogens—4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT)—including their salts, isomers, and salts of isomers, into Schedule I of the Controlled Substances Act. This action, if finalized, would impose regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I substances on persons who handle these substances in various capacities such as manufacture, distribution, research, or possession. The proposal is based on scientific and medical evaluations and recommendations from the Department of Health and Human Services (HHS). Comments on the proposal are due by October 23, 2026.